Cargando…

Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic

Finding a vaccine that can last a long time and effective against viruses with high mutation rates such as SARS-CoV-2 is still a challenge today. The various vaccines that have been available have decreased in effectiveness and require booster administration. As the professional antigen presenting c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonny, Jonny, Putranto, Terawan Agus, Irfon, Raoulian, Sitepu, Enda Cindylosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485669/
https://www.ncbi.nlm.nih.gov/pubmed/36148241
http://dx.doi.org/10.3389/fimmu.2022.989685
_version_ 1784792124450930688
author Jonny, Jonny
Putranto, Terawan Agus
Irfon, Raoulian
Sitepu, Enda Cindylosa
author_facet Jonny, Jonny
Putranto, Terawan Agus
Irfon, Raoulian
Sitepu, Enda Cindylosa
author_sort Jonny, Jonny
collection PubMed
description Finding a vaccine that can last a long time and effective against viruses with high mutation rates such as SARS-CoV-2 is still a challenge today. The various vaccines that have been available have decreased in effectiveness and require booster administration. As the professional antigen presenting cell, Dendritic Cells can also activate the immune system, especially T cells. This ability makes dendritic cells have been developed as vaccines for some types of diseases. In SARS-CoV-2 infection, T cells play a vital role in eliminating the virus, and their presence can be detected in the long term. Hence, this condition shows that the formation of T cell immunity is essential to prevent and control the course of the disease. The construction of vaccines oriented to induce strong T cells response can be formed by utilizing dendritic cells. In this article, we discuss and illustrate the role of dendritic cells and T cells in the pathogenesis of SARS-CoV-2 infection and summarizing the crucial role of dendritic cells in the formation of T cell immunity. We arrange the basis concept of developing dendritic cells for SARS-CoV-2 vaccines. A dendritic cell-based vaccine for SARS-CoV-2 has the potential to be an effective vaccine that solves existing problems.
format Online
Article
Text
id pubmed-9485669
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94856692022-09-21 Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic Jonny, Jonny Putranto, Terawan Agus Irfon, Raoulian Sitepu, Enda Cindylosa Front Immunol Immunology Finding a vaccine that can last a long time and effective against viruses with high mutation rates such as SARS-CoV-2 is still a challenge today. The various vaccines that have been available have decreased in effectiveness and require booster administration. As the professional antigen presenting cell, Dendritic Cells can also activate the immune system, especially T cells. This ability makes dendritic cells have been developed as vaccines for some types of diseases. In SARS-CoV-2 infection, T cells play a vital role in eliminating the virus, and their presence can be detected in the long term. Hence, this condition shows that the formation of T cell immunity is essential to prevent and control the course of the disease. The construction of vaccines oriented to induce strong T cells response can be formed by utilizing dendritic cells. In this article, we discuss and illustrate the role of dendritic cells and T cells in the pathogenesis of SARS-CoV-2 infection and summarizing the crucial role of dendritic cells in the formation of T cell immunity. We arrange the basis concept of developing dendritic cells for SARS-CoV-2 vaccines. A dendritic cell-based vaccine for SARS-CoV-2 has the potential to be an effective vaccine that solves existing problems. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485669/ /pubmed/36148241 http://dx.doi.org/10.3389/fimmu.2022.989685 Text en Copyright © 2022 Jonny, Putranto, Irfon and Sitepu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jonny, Jonny
Putranto, Terawan Agus
Irfon, Raoulian
Sitepu, Enda Cindylosa
Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
title Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
title_full Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
title_fullStr Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
title_full_unstemmed Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
title_short Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic
title_sort developing dendritic cell for sars-cov-2 vaccine: breakthrough in the pandemic
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485669/
https://www.ncbi.nlm.nih.gov/pubmed/36148241
http://dx.doi.org/10.3389/fimmu.2022.989685
work_keys_str_mv AT jonnyjonny developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic
AT putrantoterawanagus developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic
AT irfonraoulian developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic
AT sitepuendacindylosa developingdendriticcellforsarscov2vaccinebreakthroughinthepandemic